December 23, 2024 4:35pm

Even shorter for me as I bid adieu till after New Year

I say today what others won't, so you can do what others can't by sticking to the FACTS!

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

Never above you, never below you, always beside you!

 

Monday: The Dow closed UP +66.69 points or +0.16%, the S&P closed UP +43.22 points or +0.73% while the Nasdaq closed UP +192.29 points or +0.98%

  • Trading was thin largely muted as weak economic data seemed to sour the sentiment of the session

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • The Conference Board’s consumer confidence index for December fell to 104.7, its lowest level since September and below a Dow Jones estimate of 113.0.
  • Orders for durable goods — generally big-ticket items such as aircraft, appliances and computers — fell 1.1% in November, the largest month-over-month drop since June.

Monday’s advance/decline line at the open was neutral with 16 incliners, 16 declined and 3 flats; ending with a negative close at the close of 10 incliners, 22 decliners and 3 flats

  • The NYSE closes early Tuesday for Christmas Eve at 1 p.m. ET, and the market is shut on Christmas Day.

Metrics:  Monday, the IBB was up +0.88%, the XBI was up +0.61% while the VIX was down -1.46 points or -7.97% at 16.90

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”: 

Q4/24 – 4 positive and 12 negative closes

  • November – 1 holiday, 10 negative and 10 positive closes              
  • October: 8 positive and 15 negative sessions

 

Monday’s Closing Down (10 of 22):

  • Alnylam Pharmaceuticals (ALNY -$3.18 after Friday’s +$6.57),
  • Lenz Therapeutics (LENZ -$1.33 after Friday’s +$2.35),
  • Ultragenyx Pharmaceuticals (RARE -$0.35 after Friday’s +$0.75),
  • BioLife Solutions (BLFS -$1.01 after Friday’s +$1.28),
  • bluebird bio (BLUE -$0.84 after Friday’s -$0.73),
  • Ultragenyx Pharmaceuticals (RARE -$0.35),
  • Beam Therapeutics (BEAM -$0.31 after Friday’s +$2.16),
  • CRISPR Therapeutics (CRSP -$0.24),
  • Regenxbio (RGNX -$0.24),
  • Brainstorm Cell Therapeutics (BCLI -$0.23),

Flat (3)

  • Adverum Biotechnologies (ADVM)
  • Harvard Apparatus RT (OTCQB: HRGN)
  • Homology Medicine (FIXX)

Monday’s Closing Up (10 of 10):

  • Mesoblast (MESO +$2.60 after Friday’s -$2.13),
  • AxoGen (AXGN +$1.55 after Friday’s +$0.79),
  • Vericel (VCEL +$0.54 after Friday’s +$1.55),
  • Ionis Pharmaceuticals (IONS +$0.45),
  • uniQure NV (QURE +$0.45 after Friday’s +$1.51),
  • Moderna (MRNA +$0.20 after Friday’s -$0.17),
  • Blueprint Medicine (BPMC +$0.19),
  • MiMedx (MSXG +$0.17),
  • Verve Therapeutics (VERV +$0.16 after Friday’s +$0.58)
  • Compass Therapeutics (CMPX +$0.13),

 

The BOTTOM LINE: It’s time to try to forget 2024, I think I have had enough …

  • Merry Christmas, Happy Holidays with another year of making our portfolios a little heavier.

Wishing you many share pricing comebacks …

  • As I am off to an early leave till the New Year, 2025

 

The cell and gene therapy sector stocks ended the 3rd week of December, the final month of 2024 with ...

  • Monday of the last week of December closed negative …
  • Last Monday’s positive close with a Tuesday barely positive close followed by a Wednesday’s deeply negative with yet another Thursday negative close … followed by a Friday positive close
  • The previous week, ended with 5 negative closes
  • December’s 1st week ‘s Monday positive close was followed by negative closes on Thursday and Wednesday, Tuesday’s and then Friday’s positive close

 

As I have written “Many sector companies are engaged in cost realignment programs, which won’t be realized consequences over the next few Qs where the operating expense levels; spending on SG&A (selling, informational, and administrative) and R&D (research and development) facilitate the need to extend runways and enable expectation of clinical innovations.”

  • They had better, capital markets are floundering on follow-on offerings.

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:    

  • Monday: Mesoblast (MESO), AxoGen (AXGN) and Vericel (VCEL)
  • Friday: Alnylam Pharmaceuticals (ALNY), Lenz Therapeutics (LENZ) and Vericel (VCEL)

The worst three (3) in the session: 

  • Monday: Alnylam Pharmaceuticals (ALNY), Lenz Therapeutics (LENZ) and bluebird bio (BLUE)
  • Friday: Mesoblast (MESO), bluebird bio (BLUE) and Editas Medicine (EDIT)

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.